logo
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics.
Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics.
'Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials,' said Andrew Kress, CEO of HealthVerity. 'By providing seamless access to the industry's most comprehensive and interoperable real-world data, we empower innovators like Recursion to make data-driven decisions that streamline clinical development.'
Recursion's proprietary AI-driven approach relies on integrating diverse datasets and AI/ML models to identify novel insights into human biology and molecule design. The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites are positioned to meet enrollment goals.
'With the majority of the industry's time and resources focused on clinical trials, we see a significant opportunity to transform how clinical development is designed and executed,' said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. 'By integrating privacy-compliant real-world data from HealthVerity into Recursion OS, we are advancing our mission to optimize trial design through in silico simulations, accelerate recruitment through a patient-centric approach that includes underserved populations, and generate stronger evidence to inform development and regulatory decisions. By doing so, we are not only streamlining clinical development but also ensuring that we bring more impactful, life-changing treatments to patients faster and more efficiently'
The HealthVerity approach to real-world data acquisition and governance ensures compliance with HIPAA and other regulatory frameworks while maintaining the highest standards of patient privacy. By combining data from the nation's largest healthcare data ecosystem, HealthVerity enables precise patient journey insights, supporting clinical development, regulatory submissions, and post-market studies.
For more information, visit www.healthverity.com.
About HealthVerity
HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.
Media Contact:
HealthVerity
[email protected]
Recursion
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/healthverity-partners-with-recursion-to-enhance-clinical-trial-analytics-with-real-world-data-302429759.html
SOURCE HealthVerity, Inc.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ABL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Abacus Global Management, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
ABL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Abacus Global Management, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm

Associated Press

time19 minutes ago

  • Associated Press

ABL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Abacus Global Management, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Abacus Global investigation or if you are an Abacus Global investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Abacus Global operates as an alternative asset manager and market maker. THE REVELATION: On June 4, 2025, Morpheus Research published a report titled 'Abacus Global Management: This $740 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue By Systematically Underestimating When People Will Die.' On this news, Abacus Global's stock price fell more than 21%. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]

Qualcomm Bets $2.4 Billion On Alphawave To Power AI Data Centers
Qualcomm Bets $2.4 Billion On Alphawave To Power AI Data Centers

Yahoo

time25 minutes ago

  • Yahoo

Qualcomm Bets $2.4 Billion On Alphawave To Power AI Data Centers

Qualcomm Inc (NASDAQ:QCOM) announced on Monday that it has agreed to acquire semiconductor company Alphawave IP Group Plc for approximately $2.4 billion in cash. The purchase price implies 183 pence per share for Alphawave, implying close to a 96% premium to the price immediately before Qualcomm disclosed its interest in the company. The acquisition of Alphawave Semi aims to further accelerate, and provide key assets for, Qualcomm's expansion into data centers. Qualcomm Oryon CPU and Hexagon NPU processors are well positioned to meet the growing demand for high-performance, low-power computing, which is being driven by a rapid increase in AI inferencing and the transition to custom CPUs in data centers, the company said in a press release. Also Read: The deal, subject to regulatory and shareholder approval, will likely close in the first quarter of 2026. Qualcomm held $13.85 billion in cash and equivalents as of March 31, 2025. In May, JP Morgan analyst Samik Chatterjee said Alphawave has higher strategic importance for Qualcomm, which has recently more explicitly outlined its intent to pursue the data center market as another pillar of growth and diversification. The analyst said Alphawave's acquisition and capabilities regarding data center connectivity IP would complement its earlier acquisition of Nuvia and its capabilities for designing data center CPUs and AI inference chips based on custom ARM cores. Chatterjee expects Alphawave's breadth of capabilities to add to Qualcomm's portfolio, positioning the company to benefit from tailwinds related to strong growth in Custom silicon and ASIC adoption within AI infrastructure and development in content about connectivity products within AI data centers. He added that Alphawave's immediate contribution to Qualcomm's financial performance is unlikely material, but the company expects synergies from its entry into the broader data center TAM. Price Action: QCOM stock is trading higher by 0.19% to $149.52 premarket at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? QUALCOMM (QCOM): Free Stock Analysis Report This article Qualcomm Bets $2.4 Billion On Alphawave To Power AI Data Centers originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

US stock futures little changed ahead of US-China trade talks
US stock futures little changed ahead of US-China trade talks

Yahoo

time25 minutes ago

  • Yahoo

US stock futures little changed ahead of US-China trade talks

U.S. stock futures are little changed with inflation data due and possibly, some clarity on where the U.S. and China stand on trade issues and how the Senate may vote on the more than 1,000-page tax bill before it. The May consumer price index report, due midweek, could provide insight into whether the tariff rollercoaster is reviving inflation. It is the first full month of data since President Donald Trump announced his aggressive tariff plan on April 2. Many of the harshest tariffs have been rolled back or paused, but some have kicked in. Wholesale price data are due the next day and could give investors an idea of whether there is inflation coming down the pipeline to Americans. Wholesale prices are what businesses pay for their goods and services. At the end of the week, a new consumer sentiment reading from the University of Michigan also includes data on inflation expectations. Separately, officials from the U.S. and China are expected to hold trade talks in London, Trump said last week. The talks follow a phone call between Trump and Chinese President Xi Jinping after Trump accused China of violating terms of a tariff pause agreed on last month in Switzerland. At 5:45 a.m. ET, futures linked to the blue-chip Dow rose 0.12%, while broad S&P 500 futures added 0.12% and tech-heavy Nasdaq futures were flat. All three indexes closed higher last week, and the S&P 500 is now less than 3% from its record high. The S&P 500 topped the 6,000 mark for the first time since Feb. 21. Investors will also continue to watch the path of the One, Big Beautfil bill in the Senate after a public and fierce tit-for-tat exchange between Tesla chief executive Elon Musk and Trump over social media about the tax bill. Musk called the bill a "pork-filled Congressional spending bill is a disgusting abomination," and Trump called Musk "crazy." Cryptocurrency platform Gemini said it confidentially submitted a draft registration statement with the Securities and Exchange Commission (SEC) for an initial public offering of class A shares. The IPO is expected after the SEC review process, it said in a release. Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday. This article originally appeared on USA TODAY: US stock futures little changed ahead of US-China trade talks Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store